ProQuad® rHA Safety
Information source: Sanofi Pasteur MSD
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Measles; Mumps; Rubella; Varicella
Intervention: ProQuad® manufactured with rHA (Biological)
Phase: Phase 3
Status: Completed
Sponsored by: Sanofi Pasteur MSD Official(s) and/or principal investigator(s): Anne FIQUET, MD, Study Director, Affiliation: Sanofi Pasteur MSD
Summary
Primary objective: To describe the safety profile of a second dose of ProQuad® manufactured
with rHA when administered to children in their second year of life.
Secondary objectives: To describe the safety profile of a first dose of ProQuad®
manufactured with rHA when administered to children in their second year of life
Clinical Details
Official title: An Open-Label, Multi-Centre Study of the Safety of a 2-Dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured With Recombinant Human Albumin (rHA) When Administered to Children in Their Second Year of Life
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Solicited injection-site adverse reactions (erythema, swelling, pain)Unsolicited injection-site adverse reactions, Numeric values of temperature, Systemic Adverse Event Serious Adverse Events
Secondary outcome: Solicited injection-site adverse reactions (erythema, swelling, pain)Unsolicited injection-site adverse reactions, Numeric values of temperature, Systemic Adverse Event
Eligibility
Minimum age: 12 Months.
Maximum age: 22 Months.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy subject of either gender,
- Age from 12 to 22 months,
- Negative clinical history of infection with measles, mumps, rubella, varicella or
zoster,
- Informed consent form signed by the parent(s) or by legal representative
- Parent(s) or legal representative able to attend all schedule visits with the subject
and to understand and comply with the study procedures
Exclusion Criteria:
- Recent (≤ 3 days) history of febrile illness
- Prior receipt of measles, mumps, rubella and/or varicella vaccination, either alone
or in any combination
- Recent (≤ 30 days) exposure to measles, mumps, rubella, varicella or zoster
- Prior known sensitivity/allergy to any component of the vaccine
- Severe chronic disease,
- Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms
affecting the haematopoietic and lymphatic system
- Any severe thrombocytopenia or any other coagulation disorder that would
contraindicate intramuscular injection
- Humoral or cellular immunodeficiency,
- Current immunosuppressive therapy
- Family history of congenital or hereditary immunodeficiency
- Hereditary problems of fructose intolerance
- Known personal history of encephalopathy, seizure disorder or progressive, evolving
or unstable neurological condition,
- Known active tuberculosis
- Recent (≤ 2 days) tuberculin test or scheduled tuberculin test through Visit 3
- Receipt of immunoglobulins or blood-derived products in the past 150 days
- Receipt of an inactivated vaccine in the past 14 days
- Receipt of a live vaccine in the past 28 days
Locations and Contacts
Hvidovre, Denmark
Aalen, Germany
Bad Kreuznach, Germany
Bad Oeynhausen, Germany
Bad Säckingen, Germany
Bad Wimpfen, Germany
Bindlach, Germany
Bönnigheim, Germany
Darmstadt, Germany
Eisenberg, Germany
Ellhofen, Germany
Eschborn, Germany
Ettenheim, Germany
Falkensee, Germany
Gütersloh, Germany
Heilbronn, Germany
Herbolzheim, Germany
Jena, Germany
Langenselbold, Germany
Lauffen, Germany
Lörrach, Germany
Mannheim, Germany
Minden, Germany
Neuhaus, Germany
Nürnberg, Germany
Oberhausen, Germany
Schramberg, Germany
Solingen, Germany
Stuttgart, Germany
Traunreut, Germany
Velpke, Germany
Vilsbiburg, Germany
Wildeshausen, Germany
Zwiesel, Germany
Athens, Greece
Crete, Greece
Komotini, Greece
Larissa, Greece
Patras, Greece
Thessaloniki, Greece
Ferrara, Italy
Ragusa, Italy
Sassari, Italy
Rotterdam, Netherlands
Bueu (pontevedra), Spain
Burela (lugo), Spain
Catarroja, Spain
La Eliana, Spain
Ourense, Spain
Paiporta, Spain
Pamplona, Spain
Pontevedra, Spain
Puzol, Spain
Quart de Poblet, Spain
Redondela (pontevedra), Spain
Sagunto, Spain
San Cibrán. Aldán (pontevedra), Spain
Santiago de Compostela, Spain
Valencia, Spain
Vigo, Spain
VilagarcÃa de Arosa (pontevedra), Spain
Bromma, Sweden
Eskilstuna, Sweden
Malmö, Sweden
Östersund, Sweden
Additional Information
Starting date: October 2007
Last updated: April 3, 2009
|